Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.67 |
| ▸ | CTSK | P43235 | 5/20 | 0.67 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14405376 | 1.00 | CTSS (0.67) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL309644 | 1.00 | CTSS (0.67) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL539575 | 0.93 | CTSS (0.66) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL2574440 | 0.93 | CTSS (0.66) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL30374091 | 0.93 | CTSS (0.66) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL539574 | 0.93 | CTSS (0.66) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL7260689 | 0.91 | CTSS (0.63) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL920111 | 0.91 | CTSS (0.63) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL16470394 | 0.89 | CTSS (0.62) | CTSSCTSKLY96CTSLCTSB | |
| SCHEMBL14884529 | 0.89 | CTSS (0.62) | CTSSCTSKLY96CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777248-A | Water-based solid phase synthesis method of multi-receptor agonist polypeptide Retatrutide | 润辉生物技术（威海）有限公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2026090272-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASE | 2508 BIOSCIENCES LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260092072-A1 | INHIBITORS OF ALDOSE REDUCTASE | BARCLAYS BANK PLC (GB) | 2026-04-02 | — | — | US | disclosed |
| US-12528823-B2 | Inhibitors of aldose reductase | Applied Therapeutics, Inc. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025106386-A1 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-15 | — | — | US | disclosed |
| CN-119350471-B | Tenipout peptide synthesis method | 中肽生化有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4540267-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20100152456-A1 | Intermediate compound for synthesis of viridiofungin a derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-06-17 | — | — | US | disclosed |
| US-20100152457-A1 | Intermediate compound for synthesis of viridiofungin a derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2010-06-17 | — | — | US | disclosed |
| US-20100120686-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7638491-B2 | Administering a polypeptide having an oxime-containing non-natural amino acid, from a translation system of: a polynucleotide comprising a selector codon encoding the polypeptide, a tRNA comprising the oxime-containing amino acid | AMBRX, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080293950-A1 | Production Process of Compound Having Anti-Hcv Action and Intermediate Thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2008-11-27 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7378446-B2 | Compound having anti-HCV activity and process for producing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7378446-B2 | Compound having anti-HCV activity and process for producing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1857456-A1 | PROCESS FOR PRODUCING COMPOUND WITH ANTI-HCV POTENCY AND INTERMEDIATE FOR USE THEREIN | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120686-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | CTSS 3645/4885CTSK 2731/4885LY96 1035/4885 |
| US-20100152457-A1 | Intermediate compound for synthesis of viridiofungin a derivative | ZC3HAV1, ZC3HAV1L, MAVS | CTSS 2415/4885CTSK 1536/4885LY96 2253/4885 |
| US-12528823-B2 | Inhibitors of aldose reductase | CBR1, AKR1C3, AKR1C2 | CTSS 2388/4885CTSK 3066/4885LY96 2014/4885 |
| US-20080293950-A1 | Production Process of Compound Having Anti-Hcv Action and Intermediate Thereof | HCCS, EIF2AK2, MAVS | CTSS 2453/4885CTSK 1810/4885LY96 2394/4885 |
| US-20100152456-A1 | Intermediate compound for synthesis of viridiofungin a derivative | ZC3HAV1, ZC3HAV1L, MAVS | CTSS 2415/4885CTSK 1536/4885LY96 2253/4885 |
| US-20260092072-A1 | INHIBITORS OF ALDOSE REDUCTASE | UGCG, CBR1, LIPG | CTSS 1380/4885CTSK 2701/4885LY96 3650/4885 |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | IL1R1, IL1A, IL1B | CTSS 1403/4885CTSK 1280/4885LY96 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.